Literature DB >> 22961660

Humoral immunity in the Friend retrovirus infection model.

Kalani Halemano1, Michael S Harper, Kejun Guo, Sam X Li, Karl J Heilman, Bradley S Barrett, Mario L Santiago.   

Abstract

Major conceptual roadblocks impede the development of an HIV-1 vaccine that can stimulate a potent neutralizing antibody response. Animal models that support HIV-1 replication and allow for host genetic manipulation would be an ideal platform for testing various immunological hypotheses, but progress on this research front has been slow and disappointing. In contrast, many valuable concepts emerged from more than 50 years of studying the Friend retrovirus model. This was recently exemplified by the identification of an innate restriction gene, Apobec3, that could promote the retrovirus-specific neutralizing antibody response. Here we review both classical and recent data on humoral immunity against Friend retrovirus infection, and highlight the potential of this model for unraveling novel aspects of the retrovirus-specific antibody response that may guide HIV-1 vaccine development efforts.

Entities:  

Mesh:

Year:  2013        PMID: 22961660      PMCID: PMC4003891          DOI: 10.1007/s12026-012-8370-y

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  101 in total

1.  Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques.

Authors:  Yongjun Sui; Qing Zhu; Susan Gagnon; Amiran Dzutsev; Masaki Terabe; Monica Vaccari; David Venzon; Dennis Klinman; Warren Strober; Brian Kelsall; Genoveffa Franchini; Igor M Belyakov; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

2.  Enzymatic determination of transmissible replicating factors associated with mouse tumors.

Authors:  V RILEY
Journal:  Ann N Y Acad Sci       Date:  1963-02-15       Impact factor: 5.691

3.  Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex.

Authors:  B Chesebro; K Wehrly
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

4.  Sf-Stk kinase activity and the Grb2 binding site are required for Epo-independent growth of primary erythroblasts infected with Friend virus.

Authors:  Lisa D Finkelstein; Paul A Ney; Qing-Ping Liu; Robert F Paulson; Pamela H Correll
Journal:  Oncogene       Date:  2002-05-16       Impact factor: 9.867

5.  Retrovirus envelope protein complex structure in situ studied by cryo-electron tomography.

Authors:  Friedrich Förster; Ohad Medalia; Nathan Zauberman; Wolfgang Baumeister; Deborah Fass
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-17       Impact factor: 11.205

6.  The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.

Authors:  J M Binley; A Trkola; T Ketas; D Schiller; B Clas; S Little; D Richman; A Hurley; M Markowitz; J P Moore
Journal:  J Infect Dis       Date:  2000-08-01       Impact factor: 5.226

7.  Isolation of lactate dehydrogenase-elevating viruses from wild house mice and their biological and molecular characterization.

Authors:  K Li; T Schuler; Z Chen; G E Glass; J E Childs; P G Plagemann
Journal:  Virus Res       Date:  2000-04       Impact factor: 3.303

8.  Myd88 is required for an antibody response to retroviral infection.

Authors:  Edward P Browne; Dan R Littman
Journal:  PLoS Pathog       Date:  2009-02-13       Impact factor: 6.823

9.  Lactate dehydrogenase-elevating virus induces systemic lymphocyte activation via TLR7-dependent IFNalpha responses by plasmacytoid dendritic cells.

Authors:  Christoph G Ammann; Ronald J Messer; Karin E Peterson; Kim J Hasenkrug
Journal:  PLoS One       Date:  2009-07-01       Impact factor: 3.240

10.  Studies on the role of the host immune response in recovery from Friend virus leukemia. I. Antiviral and antileukemia cell antibodies.

Authors:  B Chesebro; K Wehrly
Journal:  J Exp Med       Date:  1976-01-01       Impact factor: 14.307

View more
  16 in total

1.  Visualizing antibody affinity maturation in germinal centers.

Authors:  Jeroen M J Tas; Luka Mesin; Giulia Pasqual; Sasha Targ; Johanne T Jacobsen; Yasuko M Mano; Casie S Chen; Jean-Claude Weill; Claude-Agnès Reynaud; Edward P Browne; Michael Meyer-Hermann; Gabriel D Victora
Journal:  Science       Date:  2016-02-18       Impact factor: 47.728

2.  Requirement for Fc effector mechanisms in the APOBEC3/Rfv3-dependent neutralizing antibody response.

Authors:  Kalani Halemano; Bradley S Barrett; Karl J Heilman; Thomas E Morrison; Mario L Santiago
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

3.  Establishment of mouse leukemia cell lines expressing human CD4/CCR5 using lentiviral vectors.

Authors:  Ya-Jing Li; Fu-Yan ZhuGe; Chang-Chun Zeng; Jin-Yang He; Ning Tan; Juan Liang
Journal:  Virus Genes       Date:  2016-12-28       Impact factor: 2.332

4.  SAMHD1 Promotes the Antiretroviral Adaptive Immune Response in Mice Exposed to Lipopolysaccharide.

Authors:  BradleyS Barrett; David H Nguyen; Joella Xu; Kejun Guo; Shravida Shetty; Sean T Jones; Kaylee L Mickens; Caitlin Shepard; Axel Roers; Rayk Behrendt; Li Wu; Baek Kim; Mario L Santiago
Journal:  J Immunol       Date:  2021-12-10       Impact factor: 5.426

Review 5.  Tetherin/BST-2: Restriction Factor or Immunomodulator?

Authors:  Sam X Li; Bradley S Barrett; Kejun Guo; Mario L Santiago
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

6.  IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3.

Authors:  Michael S Harper; Bradley S Barrett; Diana S Smith; Sam X Li; Kathrin Gibbert; Ulf Dittmer; Kim J Hasenkrug; Mario L Santiago
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

7.  Ribonuclease L is not critical for innate restriction and adaptive immunity against Friend retrovirus infection.

Authors:  Sam X Li; Bradley S Barrett; Michael S Harper; Karl J Heilman; Kalani Halemano; Amanda K Steele; Kejun Guo; Robert H Silverman; Mario L Santiago
Journal:  Virology       Date:  2013-05-29       Impact factor: 3.616

Review 8.  Mouse knockout models for HIV-1 restriction factors.

Authors:  Jan Rehwinkel
Journal:  Cell Mol Life Sci       Date:  2014-05-23       Impact factor: 9.261

9.  Fv1 restriction and retrovirus vaccine immunity in Apobec3-deficient 129P2 mice.

Authors:  Kalani Halemano; Bradley S Barrett; Sam X Li; Michael S Harper; Diana S Smith; Karl J Heilman; Mario L Santiago
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

10.  Tetherin/BST-2 promotes dendritic cell activation and function during acute retrovirus infection.

Authors:  Sam X Li; Bradley S Barrett; Kejun Guo; George Kassiotis; Kim J Hasenkrug; Ulf Dittmer; Kathrin Gibbert; Mario L Santiago
Journal:  Sci Rep       Date:  2016-02-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.